English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduA new study from Penn Medicine’s Abramson Cancer Center suggests that it’s reasonable for patients with advanced lung cancer to stop immunotherapy treatment at two years, as long as their cancer hasn’t progressed.
Tag: ASCO 2023
ASCO: Targeted therapy induces responses in HER2-amplified biliary tract cancer
An MD Anderson-led Phase II trial showed the HER2-targeted therapy zanidatamab demonstrated durable responses in patients with advanced HER2-positive biliary tract cancer. The data were presented at the 2023 ASCO Annual Meeting.
ASCO23: Sylvester Cancer Experts Available for Interviews on a Wide Range of Topics
In addition to presenting Sylvester Comprehensive Cancer Center research findings, Sylvester experts are available at ASCO to share perspectives on a wide variety of topics and studies ranging from breast cancer to sarcoma, prostate cancer, mesothelioma, melanoma, CNS tumors and more.
ASCO 23: Thyroid Cancer Precision Approaches That Incorporate Targeted Therapies and Other Treatments Are Changing the Surgeon’s Role
Historically, surgery was the first line of treatment for patients with thyroid cancer. Now, as targeted therapies and other new medications emerge, surgery for certain patients may become more of a secondary option if those treatments fail. This new context could potentially change how some procedures are conducted.
Breast, rectal, kidney, and brain cancer phase 3 trials headline Dana-Farber research at ASCO Annual Meeting
Several phase 3 studies conducted by researchers from Dana-Farber Cancer Institute show promising results for patients with rectal, brain, and kidney cancers. The results of these studies, along with dozens of others led by Dana-Farber researchers, will be presented at the 2023 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.
Two Penn Medicine Abramson Cancer Center Faculty Members Receive Top ASCO Awards
Two esteemed leaders from the Penn Medicine Abramson Cancer Center and Perelman School of Medicine at the University of Pennsylvania will be honored with 2023 Special Awards from the American Society for Clinical Oncology (ASCO), and Conquer Cancer, the ASCO Foundation, during the 2023 ASCO Annual Meeting.